Abivax
Tracked across 6 events · 59 articles · First seen Apr 01, 2026 · Last active Aug 17, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Abivax is facing a securities fraud investigation due to alleged false and/or misleading statements regarding its Phase 3 ABTECT trial for obefazimod, which revealed rare malignancy cases, causing its shares to fall sharply.
Jun 04, 2026 · 7 articles
Business
Impact: Abivax requested a temporary trading halt of its ordinary shares on Euronext Paris to facilitate the pricing and allocation of its public offering of American Depositary Shares in the United States.
Jul 01, 2026 · 7 articles
Regulatory
Impact: Abivax achieved a key regulatory milestone, aligning with FDA on NDA submission strategy for obefazimod, which supports its path to potential commercialization.
Jul 30, 2026 · 8 articles
Business
Impact: Abivax jumped over 20% after reporting positive topline results for its obefazimod study.
Apr 20, 2026 · 24 articles
Business
Impact: Abivax is mentioned as another late-stage European biotech investment made by Claret Capital Partners, indicating Claret's broader strategy in the sector.
Jun 16, 2026 · 7 articles
Business
Cocrystal Pharma, Inc., a clinical-stage biotechnology company developing antiviral therapeutics, announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings decades of experience in antiviral therapy,…
Impact: Abivax is mentioned as a company where Brosgart previously held a board position; no direct impact.
Aug 17, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Abivax live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard